💊
Pharmacology
What the Latest Research Reveals
Data last updated: 56 studies cited
How this page is produced
Generated by the ModernDoc Research Monitor from peer-reviewed literature. Every statistic is automatically checked against its cited source and screened for retractions before it is published. This page is AI-generated and has not yet been reviewed by a clinician — it is not medical advice. Read how we build and check these pages.
89%
Reduction in hospitalization/death with Paxlovid in high-risk patients
— when started within 5 days of symptoms
KEY FINDINGS
Paxlovid Efficacy
89%
95% CI: RRR 89% (95% CI: 60-96%)
Source [3]
Dexamethasone (Ventilated)
-36%
95% CI: RR 0.64 (95% CI: 0.51-0.81)
Source [1]
Tocilizumab Mortality
-14%
95% CI: OR 0.86 (95% CI: 0.78-0.94)
Source [16]
Baricitinib Mortality
-43%
95% CI: HR 0.57 (95% CI: 0.41-0.78)
Source [9]
14-day all-cause inpatient mortality with early remdesivir treatment
HR 0.76
95% CI: 95% CI: 0.73-0.79
Source [46]
28-day all-cause inpatient mortality with early remdesivir treatment
HR 0.78
95% CI: 95% CI: 0.75-0.81
Source [47]
14-day all-cause inpatient mortality with early remdesivir treatment
HR 0.76
95% CI: 95% CI: 0.73-0.79
Source [48]
28-day all-cause inpatient mortality with early remdesivir treatment
HR 0.78
95% CI: 95% CI: 0.75-0.81
Source [49]
14-day all-cause inpatient mortality with early remdesivir vs. no remdesivir
HR 0.76
95% CI: 95% CI: 0.73-0.79
Source [50]
28-day all-cause inpatient mortality with early remdesivir vs. no remdesivir
HR 0.78
95% CI: 95% CI: 0.75-0.81
Source [51]
14-day all-cause inpatient mortality with early remdesivir treatment
HR 0.76
95% CI: 95% CI: 0.73-0.79
Source [52]
28-day all-cause inpatient mortality with early remdesivir treatment
HR 0.78
95% CI: 95% CI: 0.75-0.81
Source [53]
Reduction in post-COVID-19 condition (long COVID) with nirmatrelvir/ritonavir use during acute infection
OR 0.85
95% CI: 95% CI: 0.80-0.91
Source [54]
Reduction in post-COVID-19 condition (long COVID) with nirmatrelvir/ritonavir use during acute infection
OR 0.85
95% CI: 95% CI: 0.80-0.91
Source [55]
Hospitalization or death in PANORAMIC trial (vaccinated higher-risk outpatients)
aOR 1.18
95% CI: 95% Bayesian credible interval, 0.55 to 2.62
Source [56]
Hospitalization or death in CanTreatCOVID trial (vaccinated higher-risk outpatients)
aOR 0.48
95% CI: 95% Bayesian credible interval, 0.08 to 2.23
Source [56]
Absolute hospitalization/death rates in PANORAMIC trial
0.8% vs 0.7%
Source [56]
Absolute hospitalization/death rates in CanTreatCOVID trial
0.6% vs 1.2%
Source [56]
THE TIMELINE
Antiviral Window
Days 0-5
Viral Phase
Days 1-7
Inflammatory Phase
Days 7-14
Recovery Phase
Weeks 2-4+
Antiviral Window
Days 0-5
Start Paxlovid/remdesivir within 5 days of symptoms
Key Event
Peak antiviral efficacy
Hospitalization Reduction (Outpatient Antivirals)
Paxlovid89%
Remdesivir87%
Molnupiravir30%
Source: EPIC-HR, PINETREE, MOVe-OUT Trials
Treatment Considerations for Reinfection
1st infection+Standard treatment
Reinfection+Consider alternative antivirals
Immunocompromised+Extended courses (10-14 days)
“Resistance emergence documented with prolonged exposure in immunocompromised patients”
THE HOPEFUL HORIZON
- Paxlovid shows 26% reduction in 90-day Long COVID diagnoses[14]
- Metformin demonstrated 42% reduction in Long COVID incidence[24]
- New antivirals like ensitrelvir show promising results without ritonavir interactions[15]
- Platform trials like RECOVERY enable rapid identification of effective treatments
SOURCES
- [1]RECOVERY Collaborative Group. Dexamethasone in Hospitalized Patients with Covid-19. N Engl J Med. 2021;384(8):693-704. DOI (opens in new tab)
- [2]RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2021;397(10285):1637-1645. DOI (opens in new tab)
- [3]Hammond J, Leister-Tebbe H, Gardner A, et al. Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19. N Engl J Med. 2022;386(15):1397-1408. DOI (opens in new tab)
- [4]Gottlieb RL, Vaca CE, Paredes R, et al. Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients. N Engl J Med. 2022;386(4):305-315. DOI (opens in new tab)
- [5]Jayk Bernal A, Gomes da Silva MM, Musungaie DB, et al. Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients. N Engl J Med. 2022;386(6):509-520. DOI (opens in new tab)
See a problem with the Pharmacology research summary?
Send a source correction or freshness concern. We cannot provide personal medical advice through this site.
Report a correctionSHARE THIS INFORMATION
Share with someone who needs to know